Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 138 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2021-148738

Published: 2021

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD

Blood (2019) 134 (Supplement_1): 3054.

https://doi.org/10.1182/blood-2019-123327

Published: 2019

Journal Articles

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Kyle R Crassini, MBBS,BE,BSc, Yandong Shen, BMedSc (Hon), Richard Christopherson, PhDEmeritus Professor, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 4279.

https://doi.org/10.1182/blood.V130.Suppl_1.4279.4279

Published: 2017

Journal Articles

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Blood (2017) 130 (Supplement 1): 4323.

https://doi.org/10.1182/blood.V130.Suppl_1.4323.4323

Published: 2017

Journal Articles

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Kyle R Crassini, MBBS,BE,BSc, Eva Zhang, MBBS, Shalini Balendran, MBBS, Jane Freeman, BA,FRACP,FRCPA,MBBS,MPhil,MSc, Oliver Giles Best, PhDBSc, Cecily Forsyth, FRACP, FRCPA, MBBS, Naomi Mackinlay, Ping Han, MDPhD, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2017) 130 (Supplement 1): 5321.

https://doi.org/10.1182/blood.V130.Suppl_1.5321.5321

Published: 2017

Journal Articles

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS,BE,BSc, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Richard Christopherson, PhDEmeritus Professor, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 5340.

https://doi.org/10.1182/blood.V130.Suppl_1.5340.5340

Published: 2017

Journal Articles

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

David Gottlieb, MBBS MDFRACP FRCPA, Thérèse Aurran, MD, Constantine S. Tam, MD, Mary Sartor, PhD, Rémi Letestu, MD PhD, Dennis Carney, Gavin Cull, MBBS DM FRACP FRCPA, Vincent Levy, MD PhD, Veronique Leblond, MD PhD, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 2053.

https://doi.org/10.1182/blood.V128.22.2053.2053

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Blood (2015) 126 (23): LBA-6.

https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6

Published: 2015

Journal Articles

Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5294.

https://doi.org/10.1182/blood.V126.23.5294.5294

Published: 2015

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Louise Imlay-Gillespie, BMed, Caroline Dix, MBBS, Ashley McEwan, MD, Kelly Wong, Melanie Figtree, MBBS, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA

Blood (2015) 126 (23): 2108.

https://doi.org/10.1182/blood.V126.23.2108.2108

Published: 2015

Journal Articles

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Louise Imlay-Gillespie, BMed, David Simon Kliman, MBBS, Kelly Wong, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 5038.

https://doi.org/10.1182/blood.V126.23.5038.5038

Published: 2015

Journal Articles

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

David Simon Kliman, MBBS, Louise Imlay-Gillespie, BMed, Kirsten McIlroy, MBBS, FRCPA, Anthony Gill, MBBS, MD FRCPA, Christopher Arthur, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William S Stevenson, MBBS, PhD FRACP, FRCPA, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 2656.

https://doi.org/10.1182/blood.V126.23.2656.2656

Published: 2015

Journal Articles

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MB BS, Giles Best, BSc (Hons), PhD, Sara Gabrielli, Miss, Melanie Hayes, PhD, Ying Zhu, PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 1959.

https://doi.org/10.1182/blood.V124.21.1959.1959

Published: 2014

Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 4696.

https://doi.org/10.1182/blood.V124.21.4696.4696

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Marco Montillo, MD, Susan O'Brien, MD, Alessandra Tedeschi, MD, Peter Hillmen, MB, ChB, PhD, Claire Dearden, MD, Devinder Gill, MD, Jennifer R. Brown, MD PhD, Jaqueline C. Barrientos, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Richard R. Furman, MD, Florence Cymbalista, MD, Clara Plascencia, Stephen Chang, PhD, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD

Blood (2014) 124 (21): 5654.

https://doi.org/10.1182/blood.V124.21.5654.5654

Published: 2014

Journal Articles

Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

Karin Karlsson, Mats Strömberg, Viggo Jönsson, Devinder Gill, Jens Hammerström, Jonas Wallvik, Stephen Mulligan, Kenneth Bradstock, Jan Liliemark, Gunnar Juliusson

Blood (2004) 104 (11): 3470.

https://doi.org/10.1182/blood.V104.11.3470.3470

Published: 2004

NARROW

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only